MedTrace Logo

Minimal Hepatic Encephalopathy in Hereditary Hemorrhagic Telangiectasian

NCT03586115 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-11-03

No results posted yet for this study

Summary

HHT or Rendu-Osler-Weber disease is a genetic disease with an autosomal dominant inheritance pattern, characterized by widespread telangiectases that can involve several organs including the intestinal tract and the liver. Liver involvement by HHT is characterized by widespread diffuse liver vascular malformations that give origin to arteriovenous, arterioportal and portovenous shunts. The prevalence of hepatic involvement in HHT can reach 78%. Less commonly, patients may also develop porto-systemic encephalopathy (PSE). However, there are no studies on the possibility that patients with HHT might develop mHE, a highly plausible hypothesis considering the presence of diffuse macroscopic and microscopic porto-systemic shunt in this pathological condition.

Conditions

  • Hepatic Encephalopathy
  • Minimal Brain Dysfunction

Interventions

DEVICE

Critical flicker frequency assessment

All patients will undergo critical flicker frequency assessment to evaluate the presence of minimal hepatic encephalopaty. In addition, hepatic elastometry will be assessed to evaluate the presence of advanced liver fibrosis.

Sponsors & Collaborators

  • University of Bari

    lead OTHER

Principal Investigators

  • michele barone, MD, PhD · University of Bari

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-08
Primary Completion
2020-03-21
Completion
2020-04-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03586115 on ClinicalTrials.gov